The EBiSC team is working hard to implement improvements in how EBiSC operates. Due to some short-term disruption, please get in touch via Contact@EBiSC.org if the cells you would like to access are currently listed as unavailable or you are ordering from outside of Europe.

EDi001-A

AST22, AST23, SAMEA3319992

iPSC line

Available within next 12 months
Timepoint: Confluence
Magnification: 4x
Timepoint: Confluence
Magnification: 10x
A CLIP contains information about a cell line including any specific third party obligations relating to, for example, licensing obligations or the donor consent which affect the use of the cell line.

The EBiSC Access and Use Agreement must be completed along with an individual Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org for countersignature. The EAUA must be fully signed before proceeding with your order.
A batch specific Certificate of Analysis will be available to download once you receive your EBiSC iPSC line.

General#

Cell Line

hPSCreg name EDi001-A
Alternative name(s)
AST22, AST23, SAMEA3319992
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
EDi001-A-1
(AST22-C, AST23-C)
Donor's gene variants:
SNCA, SNCA
Donor diseases:
Parkinson disease
EDi001-A-2
(AST23-1KO-3, AST22-1KO-3, AST-23_SCAKO Clone 3, AST-22_SNCAKO Clone 3)
Donor's gene variants:
SNCA, SNCA, SNCA, SNCA
Donor diseases:
Parkinson disease
EDi001-A-3
(AST23_SNCAKO Clone 1, AST22-1KO-1, AST23-1KO-1, AST22_SNCAKO Clone 1)
Donor's gene variants:
SNCA, SNCA, SNCA, SNCA
Donor diseases:
Parkinson disease
STBCi024-A
(SFC831-03-01)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi024-C
(SFC831-03-05)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi019-C
(SFC828-03-04)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi023-B
(SFC829-03-04)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi083-B
(SFC830-04-08)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi019-A
(SFC828-03-06)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi019-B
(SFC828-03-09)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi024-B
(SFC831-03-03)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
EDi008-B
(G51D-4, EDINi008-B, EDIi008-B, SAMEA3174606)
Donor's gene variants:
SNCA, SNCA, SNCA, SNCA
Donor diseases:
Parkinson disease
STBCi023-A
(SFC829-03-02)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi023-C
(SFC829-03-06)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi083-A
(SFC830-04-09)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson disease
STBCi004-B-1
(SFC832-03-06 LRRK2WT/WT C47)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
UOXFi001-B
(MK071-3)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
UOXFi001-A
(MK071-1)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
UOXFi007-A
(MK002-4)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
UOXFi001-C
(MK071-5)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
UOXFi001-D
(MK071-6)
Donor's gene variants:
GBA1
Donor diseases:
Parkinson disease
UOXFi008-A
(MK144-1)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease

Provider

Depositor University of Edinburgh (ED)
Owner College of Medicine and Veterinary Medicine
Distributors
EBiSC
Roslin Cells (RC)
Derivation country United States

External Databases

hPSCreg EDi001-A
BioSamples SAMEA3319992
Cellosaurus CVCL_AW97
Wikidata Q54831971

General Information

Publications View all related publications on hPSCreg (4)
This EBiSC line can be used for:
Yes
Research use: allowed
Clinical use: no
Commercial use: no
Subclones

Donor Information#

General Donor Information

Sex female
Age of donor (at collection) 50-54

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
This is a PD line, with the control being EDi002-A lines and CRISPR/Cas9-corrected EDi001-A-1, EDi001-A-2, EDi001-A-3 and EDi001-A-4
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • Parkinson disease
  • Parkinson's disease
  • paralysis agitans
Genetic variants
SNCA (target)
4q22.1
Heterozygous
The donor carries a triplication of the alpha-synuclein gene, resulting in 4 copies of SNCA. The copies of SNCA are situated in a heterozygous triplication configuration. See Figure 1 of Petrucci, 2015 for a graphic representation of the heterozygous triplication.
Disease associated phenotypes
  • Severe PD with dementia
Family history Strong family history of Parkinson’s disease due to autosomal dominant inheritance of SNCA triplication
Is the medical history available upon request? Y Mov Disord. 2011 Sep;26(11):2134-6. doi: 10.1002/mds.23776

Karyotyping (Donor)

Has the donor karyotype been analysed?
No

Donor Relations

Other cell lines of this donor
All cell lines of this donor's relatives
Has daughter:

External Databases (Donor)

BioSamples SAMEA3319991

hIPSC Derivation#

General

Source cell type
Source cell origin
Any portion of the organ that covers that body and consists of a layer of epidermis and a layer of dermis.
Synonyms
  • portion of skin
  • region of skin
  • skin
  • skin region
  • skin zone
show more synonyms
Age of donor (at collection) 50-54

Reprogramming method

Vector type Integrating
Vector Virus (Retrovirus)
Genes
Is the used vector excisable?
Unknown
Absence of reprogramming vector(s)?
Unknown
Reprogramming vectors silenced?
Yes
Methods used
RT-PCR

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions#

Latest released batch

Culture medium mTeSR1
Passage method EDTA
Surface coating Matrigel
O2 concentration 21
CO2 concentration 5
Temperature 37 °C
The following are the depositor culture conditions, they do not refer to any specific batch.
Surface coating Laminin
Feeder cells
No
Passage method Enzymatically
Accutase
O2 Concentration 95 %
CO2 Concentration 5 %
Medium Essential 8™
Supplements
Rock inhibitor added while passaging 10 nM

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
SSEA-4
Yes
TRA 1-60
Yes
SSEA-1
No
POU5F1 (OCT-4)
Yes
TRA 1-60
Yes
SSEA-1
No
SSEA-4
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
In vitro directed differentiation
Marker Expressed
CXCR4
Yes
Gata6
Yes
SOX17
Yes
CXCR4
Yes
Gata6
Yes
SOX17
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
In vitro directed differentiation
Marker Expressed
NCAM1
Yes
VIM
Yes
PECAM1 (CD31)
Yes
VIM
Yes
DCN
No
MIXL1
Yes
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
In vitro directed differentiation
Marker Expressed
PAX6
Yes
NeuroD1
Yes
HES5
Yes
PAX6
Yes
NEUROD1
No
HES5
Yes

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,XX
Passage number: P23
Karyotyping method: G-Banding

Other Genotyping (Cell Line)